Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16

NCT03164967 is registered in ClinicalTrials.gov with ADMA Biologics, Inc. as lead sponsor.

NCT NCT03164967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03164967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16
Lead sponsor
ADMA Biologics, Inc.
Phase
Phase 4
Overall status
Completed
Start date
December 29, 2016
Completion date
December 31, 2022
Enrollment
16 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

humoral immune response